Streetbeat News

Analyst Ratings

BMY

A significant investor has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY), with 70% of recent trades being bullish and 30% bearish. The total amount for put options is $109,642 and for call options is $396,733. Whales have been targeting a price range from $40.0 to $62.0 for Bristol-Myers Squibb over the last 3 months. The current price of BMY is up 1.94% at $62.12. Analysts have mixed ratings on the stock, with price targets ranging from $59 to $85.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 6:46 pm

MRVL

A significant bearish stance has been taken on Marvell Tech (NASDAQ:MRVL) by a large investor or institution, as indicated by unusual options activity. The sentiment among these big-money traders is split, with 41% bullish and 58% bearish. The whales have been targeting a price range from $50.0 to $95.0 for Marvell Tech over the last 3 months. The price of MRVL is currently up 0.87% at $57.87. Stifel and Barclays maintain a Buy and Overweight rating on Marvell Tech respectively, both with a price target of $75. Wolfe Research downgraded its action to Outperform with a price target of $80.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 6:46 pm

NOVA

KeyBanc Capital Markets analyst Sophie Karp has reiterated the Overweight rating on Sunnova Energy International Inc. (NOVA), but lowered the price target from $39 to $31 due to a decrease in 2023-2025 estimates. The reduction is based on 2Q results and market conditions. Karp highlights labor and operational risks within the dealer business model and policy uncertainty at federal and local levels. Despite these risks, Karp believes NOVA's current levels provide an attractive entry point for investors.

Portfolio Pulse from Nabaparna Bhattacharya

August 17, 2023 | 6:42 pm

CRSP

Citigroup analyst Yigal Nochomovitz has upgraded CRISPR Therapeutics (NASDAQ:CRSP) from Neutral to Buy, while maintaining a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 6:35 pm

AAPL

DIS

SWKS

Wedbush analyst Daniel Ives has highlighted Apple's strategic moves to dominate the live sports streaming arena, including a 10-year streaming contract with MLS. Ives suggests that Apple might target ESPN for acquisition or partnership, aligning more with its aspirations than a potential acquisition of Disney. Citi analyst Atif Malik also holds an optimistic stance on Apple, emphasizing its robust performance and the forthcoming iPhone 15 launch.

Portfolio Pulse from Anusuya Lahiri

August 17, 2023 | 6:32 pm

EQT

EQT's shares are trading higher after several analysts raised their price targets for the company. This follows the Federal Trade Commission's (FTC) completion of its review of EQT's agreement to acquire Tug Hill's upstream assets and XcL Midstream's gathering and processing assets.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 6:31 pm

SNOW

A significant bearish stance has been taken on Snowflake (NYSE:SNOW) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 80% bearish and 20% bullish. Whales have been targeting a price range from $100.0 to $270.0 for Snowflake over the last 3 months. Guggenheim has downgraded its action to Sell with a price target of $105, while Mizuho maintains a Buy rating with a price target of $180, and Exane BNP Paribas has upgraded its action to Neutral with a price target of $173.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 6:30 pm

ENPH

KeyBanc Capital Markets analyst Sophie Karp has reiterated an Overweight rating on Enphase Energy Inc (NASDAQ:ENPH), but lowered the price target from $267 to $200. The reduction reflects ongoing de-stocking in distribution channels and slowly recovering demand. Karp also noted a decrease in the target multiple due to market uncertainty. Enphase Energy's guidance for lower sales and stable margins reflects slowing shipments in the broader industry. The analyst also warned that slower than anticipated growth in demand for solar energy solutions could negatively impact operations.

Portfolio Pulse from Nabaparna Bhattacharya

August 17, 2023 | 6:24 pm

CRSP

Shares of CRISPR are being closely watched as traders circulate a note about an upgrade from Citi.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 6:23 pm

PYCR

Following Paycor HCM Inc's Q4 FY23 results, many analysts have reduced their price targets for the company. Despite beating estimates for adjusted EPS and sales, the company's projected revenues for Q1 and FY24 are below consensus. Analysts cite macroeconomic challenges and a toughening sales environment as reasons for their adjustments. Paycor's shares are currently trading lower by 5.55%.

Portfolio Pulse from Lekha Gupta

August 17, 2023 | 6:23 pm